Last reviewed · How we verify

WCK 2349 Oral

Wockhardt · Phase 1 active Small molecule

WCK 2349 Oral is a Small molecule drug developed by Wockhardt. It is currently in Phase 1 development. Also known as: levonadifloxacin (active drug).

At a glance

Generic nameWCK 2349 Oral
Also known aslevonadifloxacin (active drug)
SponsorWockhardt
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about WCK 2349 Oral

What is WCK 2349 Oral?

WCK 2349 Oral is a Small molecule drug developed by Wockhardt.

Who makes WCK 2349 Oral?

WCK 2349 Oral is developed by Wockhardt (see full Wockhardt pipeline at /company/wockhardt).

Is WCK 2349 Oral also known as anything else?

WCK 2349 Oral is also known as levonadifloxacin (active drug).

What development phase is WCK 2349 Oral in?

WCK 2349 Oral is in Phase 1.

Related